Relative to patients expressing higher levels of DYRK2, those expressing lower levels of this gene were more likely to exhibit lymph node metastasis, liver metastasis, and worse pathological typing, consistent with DYRK2 downregulation being consistent with a poorer prognosis. The gene discussed is DYRK2; the disease is metastatic malignant neoplasm in the lymph nodes.